Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481051 | 0.78 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL21128373 | 0.75 | KDM4E (0.38) | KDM4ECSNK1A1CLK4ALDH1A1SMN1; SMN2 | |
| SCHEMBL20953550 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3638928 | 0.73 | PIK3CD (0.42) | CDK2SCN2AALDH1A1 | |
| SCHEMBL1233375 | 0.71 | KDM4E (0.42) | KDM4ECSNK1A1CLK4ALDH1A1SMN1; SMN2 | |
| SCHEMBL30518204 | 0.71 | KDM4E (0.42) | KDM4ECSNK1A1CLK4ALDH1A1SMN1; SMN2 | |
| SCHEMBL31663159 | 0.71 | PLAU (0.40) | — | |
| SCHEMBL3638905 | 0.71 | PLAU (0.40) | — | |
| SCHEMBL2011726 | 0.68 | EGFR (0.38) | CDK2 | |
| SCHEMBL15732934 | 0.68 | KDM4E (0.39) | KDM4ECSNK1A1CLK4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | KDM4E 674/4885CSNK1A1 103/4885CLK4 375/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | KDM4E 873/4885CSNK1A1 110/4885CLK4 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.